Huawei CEO Ren Zhengfei said in an interview with CNBC the company's business is still strong in China.Technologyread more
The Fed is not likely to make a move on interest rates when it meets this week, but it should clear the way for a rate cut later in the summer.Market Insiderread more
U.S. President Donald Trump officially kicked off his reelection campaign Tuesday at a Florida rally where he exhorted thousands of rollicking supporters to keep advancing his...Politicsread more
BlackRock's global fixed income chief says the European Central Bank just turned up the pressure on the Federal Reserve to more toward easier policy.Market Insiderread more
Global watchdogs and top U.S. Congress members are calling for oversight of a digital asset being launched by Facebook and roughly two dozen other stakeholders.Marketsread more
Facebook's new cryptocurrency project, titled Libra and backed by the likes of Visa and Booking Holdings, is being widely embraced by market watchers.Trading Nationread more
Mortgage applications were down 3.4% from the previous week, but still up 31.6% from a year earlier, according to the Mortgage Bankers Association.Real Estateread more
Trump's remarks came a day before the Fed was set to announce its next decision on interest rates.Politicsread more
Sen. Josh Hawley, a well-known tech critic, introduced legislation on Wednesday that would remove the immunity big technology companies receive for user-posted content under...Technologyread more
Panera Bread has been testing a menu specifically for dinner and plans to expand the pilot to a new market next month.Restaurantsread more
Zuckerberg fell out of Glassdoor's top 20 CEO ranking for the first time, although his employee approval rate remains high.Technologyread more
The company said in an open letter to shareholders, its board of directors are "confident" the drugmakers acquisition of Celgene is the best path forward. The board argued the Celgene transaction will ensure the company's "strong growth continues for the foreseeable future" and will immediately establish market leadership in oncology.
"We undertook a robust and comprehensive review of our core business and strategic expansion opportunities potentially available to the company and identified the Celgene acquisition as the most attractive opportunity for shareholder value creation," the company said in a release.
Bristol has sent executives to New York to meet with institutional investors several times over the last several weeks and met with investors in Boston last Wednesday and Thursday to try and salvage the deal, a person briefed on the meetings told CNBC.
Last week, hedge funds Wellington Management and Starboard Value said they do not approve the blockbuster deal.
Wellington — which is Bristol's largest institutional holder with 135.3 million shares, or 8 percent, of its common stock — said the Celgene deal asks Bristol shareholders to accept too much risk. Starboard, which holds about 1 million shares, cited similar concerns, saying the Celgene deal was "poorly conceived and ill-advised."
Starboard said Wednesday it mailed a letter to Bristol shareholders, reiterating its belief that the deal is not in shareholders' best interests.
The deal was hard sell to Bristol shareholders from the start. The acquisition adds about $32 billion in fresh debt to Bristol's balance sheet while assuming $20 billion in Celgene's debt, the companies said at the time. After factoring in debt, the acquisition was the largest health-care deal on record, according to data compiled by Refinitiv.
Buying Celgene gives Bristol more cancer drugs at a time when its immuno-oncology portfolio struggles to keep up with rival Merck's
Shareholders will vote on the proposed acquisition next month.
The company on Wednesday reiterated that it expects the transaction to close in the second half of this year.